Published at TheDalesReport.com
The Dales Report by Rob Roscow caught up with one of two co-founders and the COO and CSO of Mydecine (NEO: MYCO) (OTCMKTS: MYCOF). In this interview, Roscow shares a little bit about Mydecine’s upcoming phase 2a clinical trials on psylocibin-assisted PTSD treatments, barriers presented by COVID, and the new novel drug candidates.
Here’s some highlights from the interview:
It’s safe to say that the psychedelics sector has learned a lot from cannabis’ occasionally-painful entry into legalization, but many concede that this is in part because psychedelic legalization is not being driven by recreational use. It’s one of the things that Roscow says is notable about the two industries – that nearly 100% of the interest is around pharmaceutical and medical application of psychedelics.
In relation to that, the amount of resources and investors has scaled tremendously. He mentions specifically is that “…the science that was gradually brought to bear in the cannabis space is being immediately brought to bear in the psychedelics space.” In comparison to cannabis, he says, the number of research dollars – and researchers themselves – are growing about four times as fast as in the cannabis space.
Roscow acknowledges that COVID has created a “headache for all clinical trials globally.” Depending on the local situation, it is hard to see patients. But he also reminds us that Mydecine was actually founded during the pandemic, so they have always been planning their trials with COVID in mind.
Mydecine’s plan to safeguard against risk to the trials is two-pronged, Roscow says. First, the number of different geographic locations will hopefully keep one site or another working, as pandemic levels will not be high at every location at the same time. Secondly, the smaller trial size means fewer points of contact with fewer patients, which makes it easier to deal with in a quarantine or semi-quarantined situation.
The recent news about the novel drug candidates has brought up a lot of questions about what the difference is in the compounds and the process that lies ahead. Roscow says that the biggest benefit behind naming Mydecine’s drug pipeline is that it gives the company a framework to explain what is happening with the pipeline behind the scenes to the public. And the reason that they are laid out in a pipeline, he says, is because they’re time-staggered in the amount of time that it will take to go through the regulatory stages for each product.
More on Mydecine’s recently announced compounds can be found here.